Phase 2 Study of HKI-272 in Subjects With Advanced Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 07 Jun 2017 Biomarkers information updated
- 21 Oct 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 17 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.